178 related articles for article (PubMed ID: 37324385)
1. Perlecan: a review of its role in neurologic and musculoskeletal disease.
Lavorgna TR; Gressett TE; Chastain WH; Bix GJ
Front Physiol; 2023; 14():1189731. PubMed ID: 37324385
[TBL] [Abstract][Full Text] [Related]
2. Schwartz-Jampel syndrome and perlecan deficiency.
Stum M; Davoine CS; Fontaine B; Nicole S
Acta Myol; 2005 Oct; 24(2):89-92. PubMed ID: 16550923
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia.
Arikawa-Hirasawa E; Le AH; Nishino I; Nonaka I; Ho NC; Francomano CA; Govindraj P; Hassell JR; Devaney JM; Spranger J; Stevenson RE; Iannaccone S; Dalakas MC; Yamada Y
Am J Hum Genet; 2002 May; 70(5):1368-75. PubMed ID: 11941538
[TBL] [Abstract][Full Text] [Related]
4. Perlecan, A Multi-Functional, Cell-Instructive, Matrix-Stabilizing Proteoglycan With Roles in Tissue Development Has Relevance to Connective Tissue Repair and Regeneration.
Hayes AJ; Farrugia BL; Biose IJ; Bix GJ; Melrose J
Front Cell Dev Biol; 2022; 10():856261. PubMed ID: 35433700
[TBL] [Abstract][Full Text] [Related]
5. Dyssegmental dysplasia, Silverman-Handmaker type: unexpected role of perlecan in cartilage development.
Arikawa-Hirasawa E; Wilcox WR; Yamada Y
Am J Med Genet; 2001; 106(4):254-7. PubMed ID: 11891676
[TBL] [Abstract][Full Text] [Related]
6. Impact of the heparan sulfate proteoglycan perlecan on human disease and health.
Arikawa-Hirasawa E
Am J Physiol Cell Physiol; 2022 Jun; 322(6):C1117-C1122. PubMed ID: 35417267
[TBL] [Abstract][Full Text] [Related]
7. Modular Proteoglycan Perlecan/
Martinez JR; Dhawan A; Farach-Carson MC
Genes (Basel); 2018 Nov; 9(11):. PubMed ID: 30453502
[TBL] [Abstract][Full Text] [Related]
8. Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene.
Arikawa-Hirasawa E; Wilcox WR; Le AH; Silverman N; Govindraj P; Hassell JR; Yamada Y
Nat Genet; 2001 Apr; 27(4):431-4. PubMed ID: 11279527
[TBL] [Abstract][Full Text] [Related]
9. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.
Farach-Carson MC; Warren CR; Harrington DA; Carson DD
Matrix Biol; 2014 Feb; 34():64-79. PubMed ID: 24001398
[TBL] [Abstract][Full Text] [Related]
10. Perlecan/HSPG2: Signaling role of domain IV in chondrocyte clustering with implications for Schwartz-Jampel Syndrome.
Martinez JR; Grindel BJ; Hubka KM; Dodge GR; Farach-Carson MC
J Cell Biochem; 2019 Feb; 120(2):2138-2150. PubMed ID: 30203597
[TBL] [Abstract][Full Text] [Related]
11. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability.
Castillo GM; Ngo C; Cummings J; Wight TN; Snow AD
J Neurochem; 1997 Dec; 69(6):2452-65. PubMed ID: 9375678
[TBL] [Abstract][Full Text] [Related]
12. Dyssegmental dysplasia Rolland-Desbuquois type is caused by pathogenic variants in HSPG2 - a founder haplotype shared in five patients.
Farshadyeganeh P; Yamada T; Ohashi H; Nishimura G; Fujita H; Oishi Y; Nunode M; Ishikawa S; Murotsuki J; Yamashita Y; Ikegawa S; Ogi T; Arikawa-Hirasawa E; Ohno K
J Hum Genet; 2024 Jun; 69(6):235-244. PubMed ID: 38424183
[TBL] [Abstract][Full Text] [Related]
13. Novel interactions of perlecan: unraveling perlecan's role in angiogenesis.
Bix G; Iozzo RV
Microsc Res Tech; 2008 May; 71(5):339-48. PubMed ID: 18300285
[TBL] [Abstract][Full Text] [Related]
14. Perlecan, a modular instructive proteoglycan with diverse functional properties.
Melrose J
Int J Biochem Cell Biol; 2020 Nov; 128():105849. PubMed ID: 32947020
[TBL] [Abstract][Full Text] [Related]
15. Review of Alterations in Perlecan-Associated Vascular Risk Factors in Dementia.
Trout AL; Rutkai I; Biose IJ; Bix GJ
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31968632
[TBL] [Abstract][Full Text] [Related]
16. Perlecan and tumor angiogenesis.
Jiang X; Couchman JR
J Histochem Cytochem; 2003 Nov; 51(11):1393-410. PubMed ID: 14566013
[TBL] [Abstract][Full Text] [Related]
17. A mouse model of Schwartz-Jampel syndrome reveals myelinating Schwann cell dysfunction with persistent axonal depolarization in vitro and distal peripheral nerve hyperexcitability when perlecan is lacking.
Bangratz M; Sarrazin N; Devaux J; Zambroni D; Echaniz-Laguna A; René F; Boërio D; Davoine CS; Fontaine B; Feltri ML; Benoit E; Nicole S
Am J Pathol; 2012 May; 180(5):2040-55. PubMed ID: 22449950
[TBL] [Abstract][Full Text] [Related]
18. Trabecular Bone Deficit and Enhanced Anabolic Response to Re-Ambulation after Disuse in Perlecan-Deficient Skeleton.
Parajuli A; Pei S; Zhao H; Martinez JR; Lu XL; Liu XS; Farach-Carson MC; Kirn-Safran CB; Wang L
Biomolecules; 2020 Jan; 10(2):. PubMed ID: 32013135
[TBL] [Abstract][Full Text] [Related]
19. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications.
Conde-Knape K
Diabetes Metab Res Rev; 2001; 17(6):412-21. PubMed ID: 11757076
[TBL] [Abstract][Full Text] [Related]
20. Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue.
Kahle MP; Lee B; Pourmohamad T; Cunningham A; Su H; Kim H; Chen Y; McCulloch CE; Barbaro NM; Lawton MT; Young WL; Bix GJ
Neuroreport; 2012 Jul; 23(10):627-30. PubMed ID: 22643235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
